Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Regorafenib in patients with metastatic colorectal cancer: a review and an update].

Recenti progressi in medicina - 1 Dec 2015

Zaniboni Alberto, Mansueto Giovanni

Abstract excerpt

Standard chemotherapy in patients with metastatic colorectal cancer is based on a combination of fluoropyrimidines, irinotecan and oxaliplatin. Regorafenib, an oral multikynase inhibitor blocking multiple disease progression-involved pathways, is a new therapeutic option in patients who already received standard therapy. In a phase III randomized, placebo-controlled study regorafenib, as compared to best...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Metastasis

Share to Phenylurea Compounds

Share to Proto-Oncogene Proteins p21(ras)

Share to Pyridines

Share to Randomized Controlled Trials as Topic

Share to Survival Rate

Source

Identifiers

PMID: 26780072
DOI: 10.1701/2094.22654

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Regorafenib in patients with metastatic colorectal cancer: a review and an update].PMID 26780072Read ↗

Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).Semantic proximity Read ↗

Regorafenib Therapy as a Third-Line Treatment for Metastatic Colorectal Cancer: A Single Center Long Term ExperienceSemantic proximity Read ↗

[Recent Advances in Systemic Chemotherapy for Metastatic Colorectal Cancer].Semantic proximity Read ↗

[Long-Term Survival of a Patient with KRAS Mutated Colon Cancer Successfully Treated with Regorafenib].Semantic proximity Read ↗

Unexpected and durable response with regorafenib in a metastatic colorectal cancer patient without KDR mutation: A case report.Semantic proximity Read ↗

Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study.Semantic proximity Read ↗

Clinical and molecular assessment of regorafenib monotherapy.Semantic proximity Read ↗

[Targeted therapies for metastatic colorectal cancer].Semantic proximity Read ↗

Cases in the management of metastatic colorectal cancer: regorafenib as second-line therapy after FOLFOXIRI plus bevacizumab in a patient with a KRAS mutation.Semantic proximity Read ↗

A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer.Semantic proximity Read ↗

KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer.Semantic proximity Read ↗

Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.